Antibody Information

General Information of This Antibody

Antibody ID	ANI0CXLFD
Antibody Name	SYD1594
Synonyms	HC-P41C Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Human IgG1-kappa
Antigen Name	Trophoblast glycoprotein (TPBG)	Antigen Info

The Activity Data of This Antibody

Antibody Activity Information 1			[1]
Dissociation Constant (Kd)	0.2	nM
Antibody Function	Confirm the effect of the drug conjugation with the anti-5T4 mAb on binding activity to target.
Antibody Antigen Binding Assay	Observed binding affinities for SYD1875 and its unconjugated antibody SYD1594 with 5T4 antigen on sensor surface using SPR.

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

SYD-1875 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04202705	Clinical Status	Phase 1
Clinical Description	A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.

References

Ref 1	Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate. Cancer Res (2021) 81 (13_Supplement): 925.
Ref 2	A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.